2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, Alves GV, Lima I, Pointreau Y, Hughes B, Aksoy S, Hetnal M, Ge JY, Brown H, Cheng J, Bidadi B, Siu LL. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncology 2020, 16: 1235-1243. PMID: 32490686, DOI: 10.2217/fon-2020-0184.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaPhase III trialsSquamous cell carcinomaChemoradiation therapyAdvanced headIII trialsCell carcinomaImmune checkpoint inhibitor pembrolizumabLarge phase III trialsCheckpoint inhibitor pembrolizumabUse of pembrolizumabCurrent treatment guidelinesAdvanced HNSCCAdvanced diseaseMaintenance therapyMetastatic HNSCCTreatment guidelinesMaintenance treatmentMultimodal treatmentPembrolizumabPatientsAntitumor activityIB dataChemoradiationHNSCC
2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgressionPoint/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.Peer-Reviewed Original ResearchConceptsDe-escalate treatmentOropharyngeal carcinomaHPV-positive oropharyngeal carcinomaNeck cancer clinical researchNew systemic agentsPhase II trialPhase III trialsTreatment-related morbidityHigh cure ratesCancer clinical researchConcurrent cisplatinII trialOropharynx cancerPrimary surgeryDose intensityIII trialsInstitutional seriesInvasive resectionMultimodality treatmentSystemic agentsSystemic therapyPrimary diseaseCure rateToxic therapiesMultimodality strategy
2018
Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma
Lee NCJ, Kelly JR, Park HS, An Y, Judson BL, Burtness BA, Husain ZA. Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncology 2018, 85: 35-39. PMID: 30220317, DOI: 10.1016/j.oraloncology.2018.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCarcinoma, Squamous CellCombined Modality TherapyFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeck DissectionNeoplasm MetastasisNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPapillomavirus InfectionsProgression-Free SurvivalProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalvage TherapyConceptsProgression-free survivalInvolved lymph nodesDistant metastasisPatterns of failureLocoregional recurrenceLymph nodesHuman papillomavirus-positive oropharyngeal carcinomaMultivariate analysisEdition American Joint CommitteeRate of DMWorse progression-free survivalHigh DM rateDedicated clinical trialsAmerican Joint CommitteeCancer (AJCC) staging systemProportional hazards regressionExternal beam radiationOropharynx cancerFree survivalNeck dissectionOropharyngeal carcinomaOverall survivalDisease recurrenceIntraoperative brachytherapyOPC patients
2017
Ent Instructions for Authors
Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Ent Instructions for Authors. Ear, Nose & Throat Journal 2017, 96: 271-272. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemoradiotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsLymph NodesMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantRetrospective StudiesSkin NeoplasmsConceptsNonmelanoma skin cancerProgression-free survivalConcurrent chemoradiationLymph nodesLocoregional controlOverall survivalSkin cancerLocalized skin cancerLymph node measurementLymph node positiveGrade 4 thrombocytopeniaPositive lymph nodesSingle tertiary centerKaplan-Meier methodAggressive clinical courseAdjuvant concurrent chemoradiationAdvanced nonmelanoma skin cancersChi-square testAdjuvant radiationAdjuvant therapyClinical courseLocal recurrenceNode positiveTertiary centerCRT patients
2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le Q, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2016, 123: 1259-1271. PMID: 27906454, PMCID: PMC5705038, DOI: 10.1002/cncr.30449.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteClinical trialsCancer InstituteRecurrent/metastatic HNSCCNational Clinical Trials NetworkNeck squamous cell carcinomaClinical trial conceptsRandomized phase 2Use of immunotherapySquamous cell carcinomaStandard of careDifferent patient populationsClinical Trials NetworkClinical trial designNew immunotherapeutic targetsPhase 2Key immune componentsDifferent immunotherapiesOncologic communityImmunotherapeutic trialsMetastatic HNSCCOropharyngeal cancerImmunotherapeutic targetCell carcinomaPatient populationTreatment de-intensification strategies for head and neck cancer
Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapyCombined Modality TherapyHead and Neck NeoplasmsHumansMinimally Invasive Surgical ProceduresOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomavirus InfectionsRadiotherapy DosageRadiotherapy, AdjuvantSquamous Cell Carcinoma of Head and NeckConceptsHigh-risk human papillomavirus infectionHuman papillomavirus infectionLong-term morbiditySquamous cell cancerSquamous cell carcinomaDe-intensification strategiesIntensive treatment regimensAltered fractionation schemesDefinitive chemoradiationAdjuvant radiationPapillomavirus infectionCell cancerImpairs qualityTreatment regimensCell carcinomaNeck cancerRecent trialsSimilar efficacySuch cancersInvasive surgeryTreatment intensityCancerRadiation dosePreliminary dataSurgery
2015
National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database
Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL. National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Medicine 2015, 4: 1828-1835. PMID: 26471244, PMCID: PMC5123708, DOI: 10.1002/cam4.546.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyComorbidityDatabases, FactualFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPopulation SurveillanceRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesYoung AdultConceptsNational Cancer DatabaseSystemic therapyPalliative therapyTreatment patternsNeck cancerCancer DatabaseClinical trialsMedicaid/uninsured statusCox proportional hazards analysisCommon treatment regimenNational treatment patternsCharlson comorbidity scorePrimary disease siteRetrospective cohort analysisProportional hazards analysisRisk of deathNeck cancer patientsMedicare/Comorbidity scoreMetastatic headOverall survivalSystemic treatmentTreatment regimenDistant metastasisKaplan-Meier
2014
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2014, 12: 1454-87. PMID: 25313184, DOI: 10.6004/jnccn.2014.0142.Peer-Reviewed Original ResearchConceptsGlottic laryngeal cancerClinical practice guidelinesLaryngeal cancerNeck cancerPractice guidelinesNCCN Clinical Practice GuidelinesEarly-stage primaryExcellent cure ratesPrinciples of surgeryDental evaluationCure rateRegional nodesRadiation therapyLymphatic drainageEarly symptomsCancerCommon typeOncologyGuidelinesEarly stagesHoarsenessSurgeryTherapySymptomsHeadTrends and variations in the use of adjuvant therapy for patients with head and neck cancer
Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer 2014, 120: 3353-3360. PMID: 25042524, DOI: 10.1002/cncr.28870.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleHead and Neck NeoplasmsHumansLogistic ModelsMaleMiddle AgedNeoplasm StagingConceptsAdjuvant therapyAdverse pathologic featuresAdjuvant chemoradiationPathologic featuresNeck cancerNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseMedicare/Medicaid insuranceImproved overall survivalHospital-level factorsCox multivariate regressionLog-rank testMultivariate logistic regressionForm of radiotherapyQuality of careAdjuvant radiotherapyOverall survivalMedicaid insuranceNetwork guidelinesCancer CenterLaryngeal cancerPractice patternsChemoradiationOral cavityPatientsOropharyngeal squamous cell carcinoma treatment
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.Peer-Reviewed Original ResearchConceptsHigh-risk human papilloma virusOropharyngeal squamous cell carcinomaHPV-unrelated cancersSquamous cell carcinomaNodal stageCell carcinomaTumor stageSquamous cell carcinoma treatmentHPV-unrelated tumorsAdvanced nodal stageRisk of deathCurrent treatment paradigmsHuman papilloma virusParaffin-embedded tissue blocksImportant causative factorAdvanced nodalDistant diseaseHPV statusCurative therapyFavorable prognosisOropharyngeal cancerRetrospective studyPapilloma virusTreatment paradigmRisk groups
2013
Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research 2013, 19: 6633-6643. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.ccr-13-0152.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCarcinoma, Squamous CellCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p16DNA RepairDNA-Binding ProteinsEndonucleasesFemaleHead and Neck NeoplasmsHeLa CellsHumansImmunoprecipitationKaplan-Meier EstimateMaleNeoplasm Recurrence, LocalRetrospective StudiesTissue Array AnalysisTreatment OutcomeConceptsMedian survivalExcision Repair Cross-Complementing Group 1Low ERCC1 expressionSquamous cell headKaplan-Meier curvesSquamous cell carcinomaCisplatin-based therapyLonger median survivalERCC1 protein expressionInitial tumor presentationAdjuvant radiotherapyMultimodality treatmentRecurrent diseaseInitial presentationMultivariable analysisRecurrent cancerTumor presentationCell carcinomaHuman papillomavirusERCC1 expressionNeck cancerSurvival differencesCell headArchival tumorsGroup 1
2012
Multi-Modality Therapy for Cancer of the Esophagus and GE Junction
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyEsophageal NeoplasmsEsophagogastric JunctionHumansMolecular Targeted TherapyNeoplasm StagingPrognosisTreatment OutcomeConceptsGastroesophageal junctionNeoadjuvant platinum-based chemotherapyPostoperative adjuvant chemotherapyPlatinum-based chemotherapyIncidence of adenocarcinomaSubgroup of patientsHigh mortality rateAdjuvant chemotherapyOpinion statementCancersInduction chemotherapyNeoadjuvant treatmentPreoperative chemoradiationDistant recurrenceModality therapySystemic therapyDistal esophagusAdvanced tumorsPredictive biomarkersMortality rateTherapeutic outcomesChemotherapyEsophagusTherapyTherapy deliveryChemoradiation
2011
Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3601-3607. PMID: 21947697, DOI: 10.1245/s10434-011-2086-4.Peer-Reviewed Original ResearchConceptsPathologic response ratePathologic responsePreoperative therapyPancreatic adenocarcinomaResponse rateComplete pathologic response rateMajor pathologic response rateMajor pathologic responseNegative lymph nodesImportant prognostic factorMinority of patientsSmaller tumor sizeMedian survival rateR0 resectionConsecutive patientsPancreatic headPartial responsePrognostic factorsImproved survivalLymph nodesTumor sizeHistopathologic examinationMinor responsePancreatic cancerTherapy occurs
2010
Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals Of Surgical Oncology 2010, 17: 2832-2838. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.Peer-Reviewed Original ResearchConceptsR0 resection ratePreoperative therapyPreoperative chemoradiationResection ratePancreatic adenocarcinomaVenous involvementBilateral narrowingUnilateral narrowingSurvival rateBorderline resectable pancreatic adenocarcinomaBorderline resectable pancreatic cancerMargin-negative resection rateMedian overall survival rateHigher R0 resection rateImproved overall survivalResectable pancreatic cancerNegative lymph nodesMargin-negative resectionOverall survival rateResectable pancreatic adenocarcinomaSuperior mesenteric veinPreoperative computed tomographyType IIBackgroundPancreatic adenocarcinomaBorderline resectabilityUse of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansLinear ModelsLymph Node ExcisionMaleMiddle AgedRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesTreatment FailureConceptsIntensity-modulated radiotherapyLow-neck fieldLower neckDisease-free survival ratesPercutaneous endoscopic gastrostomy tubeNeck fieldSingle-institution studySquamous cell carcinomaLog-rank testTreatment of headAnterior photon fieldAnterior low-neck fieldClinical detrimentCurative intentMedian ageClinical outcomesGastrostomy tubeNeck diseasePEG tubeCell carcinomaNeck cancerPhysician preferenceRegional failureStage IIIPatientsInitial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: 1020-1025. PMID: 20231078, DOI: 10.1016/j.ijrobp.2009.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, Squamous CellCetuximabCombined Modality TherapyDrug Administration ScheduleErlotinib HydrochlorideFeasibility StudiesFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalProtein Kinase InhibitorsQuinazolinesRadiotherapy DosageRetreatmentTreatment OutcomeConceptsDose-limiting toxicityMaintenance erlotinibPrimary HNCCohort IIICohort IINeck cancerCohort IPrimary headRadiation therapyPhase I dose-escalation trialPercutaneous endoscopic gastrostomy (PEG) tube placementAcute grade 3 toxicityGrade 4 acute toxicityI dose-escalation trialEndoscopic gastrostomy tube placementGrade 3 dysphagiaGrade 3 osteoradionecrosisNew primary headGrade 3 toxicityDose-escalation trialPhase I trialGastrostomy tube placementErlotinib dailyMaintenance therapyPrior radiation
2008
A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals Of Oncology 2008, 19: 977-983. PMID: 18296423, DOI: 10.1093/annonc/mdm591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCombined Modality TherapyDisease-Free SurvivalDocetaxelDrug Administration ScheduleDrug Resistance, NeoplasmEpothilonesFemaleHead and Neck NeoplasmsHematologic DiseasesHumansInfusions, IntravenousMaleMiddle AgedPaclitaxelPeripheral Nervous System DiseasesRecurrenceSalvage TherapySurvival AnalysisTaxoidsConceptsTaxane-naive patientsArm BEastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group StudyRecurrent squamous cell cancerSensory/motor neuropathyRandomized phase II studyMetastatic/recurrent diseaseCommon grade 3Grade 3 neuropathyPhase II studyPrimary end pointSquamous cell cancerSquamous cell carcinomaEligible patientsPrior regimensWeekly ixabepiloneRecurrent diseaseII studyMedian survivalPartial responsePerformance statusMotor neuropathyCell cancerCell carcinoma
2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 2006, 24: 135-140. PMID: 16502351, DOI: 10.1007/s10637-006-5934-5.Peer-Reviewed Original ResearchConceptsPathologic complete response rateThrombo-embolic eventsParallel design studyModality therapyResponse rateAdvanced esophageal cancer patientsRandomized phase IIComplete response rateEvidence of diseaseProgression-free survivalEsophageal cancer patientsOverall response ratePhase IIAdjuvant paclitaxelConcurrent radiotherapyEligible patientsPreoperative treatmentMusculoskeletal toxicityOverall survivalResectable adenocarcinomaDisease relapsePreoperative stagingTreatment armsDisease improvementContinuous infusion
2004
Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates
Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates. Journal Of Clinical Oncology 2004, 23: 17-23. PMID: 15545666, DOI: 10.1200/jco.2005.09.048.Peer-Reviewed Original ResearchConceptsConservative surgeryFree rateBreast cancerYale-New Haven HospitalSequence of radiotherapyLocal relapse rateCompletion of radiationBreast cancer patientsOverall survivalMargin statusNodal statusRelapse rateConcurrent administrationT stageRetrospective studyCancer patientsProgesterone statusPatientsStage ITamoxifenLocal controlConcurrent useCancer cellsSignificant differencesCancer